Thyroid:代谢综合征与甲状腺癌风险

2020-06-12 MedSci原创 MedSci原创

代谢综合征与普通人群甲状腺癌的风险增加有关。肥胖人群中,代谢综合症与甲状腺癌的风险更为显著。在男性中,代谢综合征和肥胖与较高的甲状腺癌风险有关,在女性中则无关联。

代谢综合征及其成分与甲状腺癌风险之间的关系尚不清楚。近日,甲状腺疾病领域权威杂志Thyroid上发表了一篇研究文章,研究人员进行了一项大规模、全国性,基于人群的队列研究,以探究这种关联。

研究人员分析了2009年1月1日至12月31日期间韩国国民健康保险健康检查数据库中9890917例无甲状腺癌的成年人。受试者具有代谢综合征五个组分至少三个:腹部肥胖、高甘油三酯血症、低高密度脂蛋白胆固醇、高血压和高血糖症。多变量Cox比例风险模型用于评估甲状腺癌的风险。

在平均7.2年的随访期间,研究人员新发现了77133例甲状腺癌病例。代谢综合征患者的甲状腺癌风险高于非代谢综合征患者(HR为1.15;95%CI为1.13-1.17)。在肥胖组(HR为1.10,95%CI为1.07-1.13)中,代谢综合征与甲状腺癌风险之间的相关性显著,而非肥胖组(HR为1.002,95%CI为0.98-1.03)则无统计学意义。代谢综合征对甲状腺癌风险的影响因肥胖而异(相互作用P=0.017)。具有代谢综合征所有五个组分的受试者比没有任何组分的人发生甲状腺癌风险高出39%(HR为1.39;95%CI为1.33-1.44)。肥胖组(HR为1.29;95%CI为1.21-1.38)中具有所有五种组分的受试者患甲状腺癌的风险较高,而非肥胖组则不高(HR为1.06;95%CI为0.98-1.14)。代谢综合症组分的数量和肥胖之间存在显著的相互作用(相互作用P<0.001)。由于肥胖和代谢综合症对甲状腺癌风险的综合影响,与无代谢综合征的男性相比,代谢综合症的肥胖男性甲状腺癌风险最高(HR为1.58,95%CI为1.52-1.64),但代谢综合征的肥胖女性则没有。

由此可见,代谢综合征与普通人群甲状腺癌的风险增加有关。肥胖人群中,代谢综合症与甲状腺癌的风险更为显著。在男性中,代谢综合征和肥胖与较高的甲状腺癌风险有关,在女性中则无关联。

原始出处:

Joo-Hyun Park,et al.Metabolic syndrome and the risk of thyroid cancer: A nationwide population-based cohort study.Thyroid.2020.https://www.liebertpub.com/doi/10.1089/thy.2019.0699

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=962522, encodeId=03ae96252254, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ef55239936, createdName=453693334_82560863, createdTime=Tue May 04 00:00:38 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061942, encodeId=07ae2061942be, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 20 20:08:26 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900011, encodeId=d25090001105, content=期待大规模研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0cc51876313, createdName=ms4408957580485341, createdTime=Tue Nov 17 22:08:04 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889832, encodeId=529d8898325c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Sat Oct 03 09:55:15 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431850, encodeId=9cf11431850a8, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jun 14 04:08:26 CST 2020, time=2020-06-14, status=1, ipAttribution=)]
    2021-05-04 453693334_82560863

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=962522, encodeId=03ae96252254, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ef55239936, createdName=453693334_82560863, createdTime=Tue May 04 00:00:38 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061942, encodeId=07ae2061942be, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 20 20:08:26 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900011, encodeId=d25090001105, content=期待大规模研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0cc51876313, createdName=ms4408957580485341, createdTime=Tue Nov 17 22:08:04 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889832, encodeId=529d8898325c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Sat Oct 03 09:55:15 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431850, encodeId=9cf11431850a8, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jun 14 04:08:26 CST 2020, time=2020-06-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=962522, encodeId=03ae96252254, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ef55239936, createdName=453693334_82560863, createdTime=Tue May 04 00:00:38 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061942, encodeId=07ae2061942be, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 20 20:08:26 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900011, encodeId=d25090001105, content=期待大规模研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0cc51876313, createdName=ms4408957580485341, createdTime=Tue Nov 17 22:08:04 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889832, encodeId=529d8898325c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Sat Oct 03 09:55:15 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431850, encodeId=9cf11431850a8, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jun 14 04:08:26 CST 2020, time=2020-06-14, status=1, ipAttribution=)]
    2020-11-17 ms4408957580485341

    期待大规模研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=962522, encodeId=03ae96252254, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ef55239936, createdName=453693334_82560863, createdTime=Tue May 04 00:00:38 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061942, encodeId=07ae2061942be, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 20 20:08:26 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900011, encodeId=d25090001105, content=期待大规模研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0cc51876313, createdName=ms4408957580485341, createdTime=Tue Nov 17 22:08:04 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889832, encodeId=529d8898325c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Sat Oct 03 09:55:15 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431850, encodeId=9cf11431850a8, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jun 14 04:08:26 CST 2020, time=2020-06-14, status=1, ipAttribution=)]
    2020-10-03 carolinewy

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=962522, encodeId=03ae96252254, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ef55239936, createdName=453693334_82560863, createdTime=Tue May 04 00:00:38 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061942, encodeId=07ae2061942be, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 20 20:08:26 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900011, encodeId=d25090001105, content=期待大规模研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0cc51876313, createdName=ms4408957580485341, createdTime=Tue Nov 17 22:08:04 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889832, encodeId=529d8898325c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Sat Oct 03 09:55:15 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431850, encodeId=9cf11431850a8, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jun 14 04:08:26 CST 2020, time=2020-06-14, status=1, ipAttribution=)]

相关资讯

JAMA:营养和行为干预对代谢综合征患者饮食习惯的影响

鼓励低能量的地中海饮食和体育活动的干预措施可提高低能量饮食依从性

Clinica Chimica Acta:血清碱性磷酸酶水平与代谢综合征呈正相关?

血清碱性磷酸酶(ALP)是一种肝胆或骨骼疾病的有用标志物,近年来已成为慢性低度炎症和心脏代谢疾病的生物标志物。本研究旨在探讨健康成年人血清ALP水平与代谢综合征(MetS)的关系。 这项横断面研究使用2008年至2011年韩国国民健康与营养检查调查的数据,调查了19至75岁的7101名男性和8873名女性的血清ALP水平与MetS的关系。 通过对血清ALP四分位数(Q1:≤190U / L

Cell Metab:拜拜夜宵!Cell子刊证实限时饮食可显著改善代谢综合征患者健康指标!

代谢综合症是导致2型糖尿病和心血管疾病的风险因素,其一线疗法为积极的饮食干预辅助药物治疗,促使患者减少热量摄入、增加体育锻炼。但由于缺乏自制力和依从性,患者往往不能真正回归到健康的生活方式中来。

BMJ:非诺贝特辅助他汀治疗可降低代谢综合征患者主要心血管事件风险

非诺贝特作为他汀治疗辅助药物显著降低了代谢综合征患者的主要心血管事件风险

Radiology:或许这才是靠谱体脂率测量的方法!

代谢综合征是与肥胖和异位脂肪分布是有相关性的。

Stroke:房颤患者代谢综合征与缺血性卒中风险

由此可见,在调整CHA2DS2-VASc变量后,MetS的存在与缺血性卒中没有显著相关性。考虑MetS不太可能改善AF患者的卒中预测。